Evidence map›Paper›PMID 32509776›Full record

ArticleFrontiers in cell and developmental biology2020

Endothelial Progenitor Cells Produced From Human Pluripotent Stem Cells by a Synergistic Combination of Cytokines, Small Compounds, and Serum-Free Medium.

Simon Farkas, Pavel Simara, Daniela Rehakova, Lenka Veverkova, Irena Koutna

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cell and developmental biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Dual ROS modulation by MnOTheranostics · 2026
    Article
  3. Review
  4. Review
  5. Review
  6. Therapeutic Potential of Endothelial Progenitor Cells in Pulmonary Diseases.American journal of respiratory cell and molecular biology · 2021
    Review
  7. Review
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Simon FarkasDepartment of Histology and Embryology, Theoretical Departments, Faculty of Medicine, Masaryk University, Brno, Czechia.
Pavel SimaraDepartment of Histology and Embryology, Theoretical Departments, Faculty of Medicine, Masaryk University, Brno, Czechia.
Daniela RehakovaInternational Clinical Research Center, St. Anne's University Hospital Brno, Brno, Czechia.
Lenka VeverkovaI. Surgery Department, St. Anne's University Hospital Brno, Brno, Czechia.
Irena KoutnaDepartment of Histology and Embryology, Theoretical Departments, Faculty of Medicine, Masaryk University, Brno, Czechia.
St. Anne's University Hospital Brno · CZMasaryk University · CZUniversity Hospital Brno · CZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human pluripotent stem cells (hPSCs) are a promising source of autologous endothelial progenitor cells (EPCs) that can be used for the treatment of vascular diseases. However, this kind of treatment requires a large amount of EPCs. Therefore, a highly efficient, robust, and easily reproducible differentiation protocol is necessary. We present a novel serum-free differentiation protocol that exploits the synergy of multiple powerful differentiation effectors. Our protocol follows the proper physiological pathway by differentiating EPCs from hPSCs in three phases that mimic

Indexed as

differentiationendothelial progenitorshESChiPSChPSCmesodermprotocol

Identifiers

PMID32509776
PMCPMC7249886
OpenAlexW3025323599

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.